Business Wire

NJ-LABVANTAGE-SOLUTIONS

25.4.2022 14:02:07 CEST | Business Wire | Press release

Share
New LabVantage Forensic Navigator™ Seamlessly Manages Vast Data Flows Over the Entire Forensic Life Cycle

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced the introduction of LabVantage Forensic NavigatorTM , an industry expert-built informatics platform designed to seamlessly manage the vast amounts of forensic evidence and data used throughout the entire criminal justice life cycle.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005012/en/

Forensic Navigator handles data flows in real time, from the evidence gathered at the crime scene through the ultimate resolution of the investigation. It accelerates the investigative process by streamlining, connecting, and analyzing all aspects of a criminal case, including evidence collection, property management, forensic lab analyses, medical examiner processes and reports, investigative activities, and legal proceedings. Forensic Navigator also includes critical tools to ensure quality management and regulatory compliance, in addition to forensic intelligence capabilities that allow users to gain insight from all data generated spanning investigations even across cases.

“LabVantage Forensic Navigator is a breakthrough informatics platform designed to increase the efficiency, effectiveness and accuracy of criminal justice operations,” said Mikael Hagstroem, Chief Executive Officer of LabVantage Solutions. “Forensic Navigator is built on the foundation of our industry-leading LIMS platform, but our developers went beyond those capabilities to produce a comprehensive system capable of managing and integrating the enormous amount of information generated during criminal investigations. At LabVantage we aim to bring the benefits of digital transformation to a variety of data-intensive industries, and we are proud to introduce this important new product purpose-built for the criminal justice sector, where data abounds and the stakes are so high.”

Forensic Navigator uses browser-based technology that is cloud hosted and is available in either SaaS or on-premise formats. It is a single, integrated, configurable platform that eliminates the need for customization. Forensic Navigator supports compliance with ISO17025, CALEA and other accreditations. It encompasses the entire forensic life cycle with best-in-class cybersecurity protection. Forensic Navigator’s forensics intelligence software provides insights from investigative data and is enhanced by predictive analysis through its forensic intelligence capabilities.

Robin MacDonald, PhD, Senior Product Specialist at LabVantage, spent more than a decade managing a forensic unit serving one of the largest counties in Florida. Dr. MacDonald noted, “The comprehensive data management capabilities of LabVantage Forensic Navigator would have been a huge help when I was a front-line forensic scientist at a busy law enforcement agency. In the complex, highly regulated criminal justice environment, Forensic Navigator’s ability to seamlessly manage all the evidence and data needed for investigations is a major advantage, eliminating the burden and inefficiency of implementing, maintaining, and coordinating multiple data management systems. It allows law enforcement personnel to enter data in real time, make examination requests and check status from a secure web-based portal. We offer a go-live plan that simplifies implementation and LabVantage’s track record of exceptional customer service means that expert user support is always available.”

Key advantages of LabVantage Forensic Navigator include:

  • Advanced technology - HTML5-based platform with advanced predictive analytics via forensic intelligence.
  • Browser-based - Cloud hosted and available in either SaaS or on-premise formats.
  • Configurable - With industry best practices, including data integrity and cybersecurity protection.
  • Online portal - For evidence pre-log, exam requests, status updates, and released reports.
  • Dashboards - View all key performance indicators at a glance.
  • Instruments - Integration and interface with most networkable instruments.
  • Collaboration - Enables rapid access to shared data. Duplicative entry is never needed.
  • Chain of custody - Includes person-to-person and person-to-secure-location transfers, with reporting options.
  • Case management – Facilitates organizing all aspects of the case.
  • Crime scene – Upload images and videos, capture scene-processing activities, and generate reports.
  • Property management – Easily locate evidence and manage disposition activities.
  • Medical examiner - Document external and autopsy observations, track next-of-kin, capture interviews.
  • Laboratory – Track evidence through intake, examination assignment, testing, and reporting.
  • Electronic lab notebook - Tracking support throughout the entire analytical life cycle.
  • Reagents - Manage reagents, standards, and other laboratory consumables.
  • Forensic intelligence - Pool siloed data for rapid resolution of cases and confidence in results.
  • SDMS - Collect and secure files maintained throughout the lab with full traceability and search functions.

For more information on LabVantage Forensic Navigator click here or email info@labvantage.com .

About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/labvantage

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye